Acrux Ltd
ASX:ACR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Acrux Ltd
ASX:ACR
|
6.1m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Acrux Ltd
Glance View
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a portfolio of generic topical prescription pharmaceutical products which use dermal and transdermal drug delivery technology. The firm's product pipeline includes Evamist, Lenzetto, Jublia, EMLA and Testosterone Topical Solution. The firm's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The products offered by the Company are the testosterone topical solution to treat adult males who have low or no testosterone and Estradiol MDTS to treat moderate to severe hot flushes commonly associated with menopause. The company is also developing a range of topical and dermatological generic products for the United States market. The firm operates in the United States, Europe and other markets.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Acrux Ltd is -131.3%, which is below its 3-year median of -72.5%.
Over the last 3 years, Acrux Ltd’s Net Margin has increased from -192.7% to -131.3%. During this period, it reached a low of -192.7% on Jun 30, 2022 and a high of -4.9% on Dec 31, 2023.
